DDX18

Across TCGA pan-cancer cohorts, DDX18 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DDX18 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DDX18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDX18 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, SARC, and LUSC are the cancer types where DDX18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.179	0.687	<.001	15	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	OS	Median	II,III,IV	0.172	0.732	.012	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
PRAD	DFS	Median	All	0.154	0.777	<.001	4	view →
UCEC	DFS	Median	All	0.934	0.625	.034	4	view →
SKCM	DFS	Median	III,IV	1.000	0.469	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DDX18–BLCA (OS)

Open the BLCA breakdown →